1[1]Babaian R. NCCN Prostate Cancer Early Detection.Clinic Practice Guidelines in Oncology-V. 1 [DB]. National Comprehensive Cancer Network, 2004.
2[2]Fleisher M, Dnistrian AM, Sturgeon CM, et al. Practice guidelines and recommendations for use tumor markers in the clinic[M]. Washington DC:AACC Press, 2002.
3[3]Semjonow A, Albrecht W, Bialk P, et al. Tumor markers in prostate cancer:EGTM recommendations[J]. Anticancer Res, 1999,19(4A):2799-2801.
4[4]Duffy MJ, McGing P, McSweeney J. Guidelines for the use of tumor markers, produced on behalf of the scientific committee of the ACBI[M]. 2nd ed. 2000.
5[5]Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges[J]. JAMA, 1993,270(7):860-864.
6[6]Paul R, Breul J, Hartung R. Prostate-specific antigen density and age-specific prostate-specific antigen values:the solution of prostate cancer screening [J]? Eur Urol,1995,27(4):286-291.
7[7]Schmid HP. Prostate specific antigen doubling time in diagnosis and follow-up of patients with prostate cancer [J]. Tumour Marker Update, 1996,8:71-77.
8[8]D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy[J]. N Engl J Med, 2004,351(2):125-135.
9[9]Bangma CH, Kranse R, Blijenberg BG, et al. The value of screening tests in the detection of prostate cancer. Part Ⅱ: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density[J]. Urology, 1995,46(6):779-784.
10[10]Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening[J]. JAMA,1995,274(15):1214-1220.
3Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer[J]. Clin Chem,2004,50(6) :1017-1025.
4aStamey TA. Preoperation serum prostate-specific antigen (PSA) below 10 μg/L predicats neither the presence of prostate cancer nor the rate of postoperation PSA failure[ J]. Clin Chem ,2001,47 (4) :631-634.
5Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prosrate cancer among men with a prostate-specific antigen level ≤4 μg/L[ J]. N Engl ned,2004,350(22) :2239-2246.
6Reeker F, Kwiatkowski MK, Pironen T, et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostatespecific antigen [ J ]. Urology, 2000,55 ( 3 ) :481-485.
7van Gils MP,Hessels D,van Hooij O,et al. The time-resolved fluorescence based PCA3 test on urinary sediments after digital rectal examination [ J ]. Clin Cancer Res,2007,13 (3) :939-943.
8Marks KS, Fradet Y, Deras IL, et al. PCA3 molecule urine assay for prostate cancer in men undergoing repeat biopsy [ J]. Urology, 2007,69 ( 3 ) :532-535.
9Paul B, Dhir R, Landsittel D, et al.Detection of prostate cancer with a blood-based assay for early prostate cancer antigen [ J ]. Cancer Res ,2005 ,65 ( 10 ) :4097 -4100.
10Leman ES, Cannon GW,Trock BJ,et al. EPCA-2 :a highly specific serum marker for prostate cancer [ J ]. Urology, 2007,69 (4) : 714-720.
